| Primary information |
|---|
| SALID | SAL_16436 |
| Biomarker name | Imidazole |
| Biomarker Type | Diagnostic |
| Sampling Method | Saliva samples collected from healthy-controls (n = 12), mild cognitive impairment (MCI) sufferers (n = 8), and AlzheimerÕs disease (AD) patients (n = 9) |
| Collection Method | Study participants were asked to rinse their mouths with water for 5 min and were subsequently instructed to spit into 50-cc Falcon tubes |
| Analysis Method | H-NMR |
| Collection Site | Supernatant Saliva |
| Disease Category | Neurological Disorder |
| Disease/Condition | Mild Cognitive Impairment (MCI) |
| Disease Subtype | NA |
| Fold Change/ Concentration | NA |
| Up/Downregulated | Increase |
| Exosomal | NA |
| Organism | Homo sapiens |
| PMID | 28453477 |
| Year of Publication | 2017 |
| Biomarker ID | 795 |
| Biomarker Category | Metabolite |
| Sequence | C1=CN=CN1 |
| Title of study | Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics |
| Abstract of study | Using 1H NMR metabolomics, we biochemically profiled saliva samples collected from healthy-controls (n = 12), mild cognitive impairment (MCI) sufferers (n = 8), and Alzheimer's disease (AD) patients (n = 9). We accurately identified significant concentration changes in 22 metabolites in the saliva of MCI and AD patients compared to controls. This pilot study demonstrates the potential for using metabolomics and saliva for the early diagnosis of AD. Given the ease and convenience of collecting saliva, the development of accurate and sensitive salivary biomarkers would be ideal for screening those at greatest risk of developing AD. |